About: Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2
Creator	Liu, Lei Tan, Li Wang, Qiongshu Ding, Yinjuan Kou, Guomei Liu, Wanbing Ni, Wenxu Tang, Shi Wu, Wanlei Zheng, Shangen Zheng, Yaqiong Xiong, Zhou
Source	Medline; PMC; WHO
abstract	At present, PCR-based nucleic acid detection cannot meet the demands for coronavirus infectious disease (COVID-19) diagnosis. Two hundred fourteen confirmed COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command of the People’s Liberation Army between 18 January and 26 February 2020 were recruited. Two enzyme-linked immunosorbent assay (ELISA) kits based on recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein (rN) and spike protein (rS) were used for detecting IgM and IgG antibodies, and their diagnostic feasibility was evaluated. Among the 214 patients, 146 (68.2%) and 150 (70.1%) were successfully diagnosed with the rN-based IgM and IgG ELISAs, respectively; 165 (77.1%) and 159 (74.3%) were successfully diagnosed with the rS-based IgM and IgG ELISAs, respectively. The positive rates of the rN-based and rS-based ELISAs for antibody (IgM and/or IgG) detection were 80.4% and 82.2%, respectively. The sensitivity of the rS-based ELISA for IgM detection was significantly higher than that of the rN-based ELISA. We observed an increase in the positive rate for IgM and IgG with an increasing number of days post-disease onset (d.p.o.), but the positive rate of IgM dropped after 35 d.p.o. The positive rate of rN-based and rS-based IgM and IgG ELISAs was less than 60% during the early stage of the illness, 0 to 10 d.p.o., and that of IgM and IgG was obviously increased after 10 d.p.o. ELISA has a high sensitivity, especially for the detection of serum samples from patients after 10 d.p.o., so it could be an important supplementary method for COVID-19 diagnosis.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1128/jcm.00461-20
bibo:pmid	32229605
has license	no-cc
sha1sum (hex)	acc142378678822969a44591414c875fd445f463
schema:url	https://doi.org/10.1128/jcm.00461-20
resource representing a document's title	Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2
has PubMed Central identifier	PMC7269413
has PubMed identifier	32229605
schema:publication	J Clin Microbiol
resource representing a document's body	covid:acc142378678822969a44591414c875fd445f463#body_text
is schema:about of	named entity 'high' named entity 'sensitivity' named entity 'Army' named entity 'D.P.' named entity 'NUCLEIC ACID DETECTION' named entity 'COVID-19' named entity 'DROPPED' named entity 'DIAGNOSED' covid:arg/acc142378678822969a44591414c875fd445f463 named entity 'antibody' named entity 'detection' named entity 'IgM' named entity 'based' named entity 'd.p.o.' named entity 'IgG' named entity 'stage' named entity 'IgM' named entity 'ELISAs' named entity 'IgG antibodies' named entity 'COVID' named entity 'nucleocapsid protein' named entity 'serum samples' named entity 'IgM' named entity 'nucleic acid detection' named entity 'IgM' named entity 'ELISAs' named entity 'Central Theater Command' named entity 'Antibodies' named entity 'acid' named entity 'IgG' named entity 'ELISAs' named entity 'nucleocapsid' named entity 'negative control' named entity 'SARS-CoV-2' named entity 'd.p.o.' named entity 'IgG' named entity 'serodiagnosis' named entity 'antibodies' named entity 'structural proteins' named entity 'Serum sample' named entity 'ELISAs' named entity 'SARS' named entity 'false-negative' named entity 'sputum' named entity 'antibody' named entity 'IgG' named entity 'receptor' named entity 'ELISAs' named entity 'host cells' named entity 'ELISAs' named entity 'IgG' named entity 'ELISAs' named entity 'ORFs' named entity 'serum samples' named entity 'statistically significant' named entity 'IgG' named entity 'IgM' named entity 'IgG' named entity 'COVID-19' named entity 'IgG' named entity 'angiotensin-converting enzyme 2' named entity 'COVID' named entity 'Europe' named entity 'IgG antibody' named entity 'SARS-CoV-2' named entity 'antigens' named entity 'coronavirus' named entity 'IgM' named entity 'virus' named entity 'RNA-based'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software